Calidi Biotherapeutics adds former Genentech, Celgene executive Corsee Sanders to board
CLDI•Board appointment
Calidi Biotherapeutics added Corsee Sanders, Ph.D. to its board.
Sanders previously advised Celgene’s CMO following its Juno acquisition, where she served as EVP of Development Operations. She later served as a transition advisor to Bristol Myers Squibb following its acquisition of Celgene.
Sanders spent 23 years at Genentech/Roche, including six years as SVP and global head of clinical operations and industry collaboration.
